Safety of vaginal estrogen in breast cancer survivors: Current evidence on systemic absorption and oncologic outcomes.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing existing literature without systematic review or meta-analysis methodology reported.
PubMed 41864136 · doi:10.1016/j.maturitas.2026.108914
What was done
This narrative review synthesized literature on postmenopausal vaginal estrogen use and breast cancer risk. The authors evaluated systemic absorption, breast cancer incidence, recurrence risk, and breast cancer mortality, including outcomes among patients receiving aromatase inhibitor therapy and comparative data between different vaginal estrogen formulations.
What was found
The abstract provides no numerical data, hazard ratios, or statistical metrics. The authors report that vaginal estrogen produces minimal systemic absorption and is not associated with an increased incidence of breast cancer, cancer recurrence, or breast cancer-specific mortality. For breast cancer survivors taking aromatase inhibitors, vaginal estrogen was not associated with increased mortality, though recurrence risk evidence remains controversial. No head-to-head trials comparing specific vaginal estrogen formulations in breast cancer survivors were identified.
Why it matters
Genitourinary syndrome of menopause significantly impacts quality of life in breast cancer survivors. This synthesis supports recent regulatory updates, such as FDA removal of certain boxed warnings, distinguishing local vaginal estrogens from systemic hormone therapy to guide individualized clinical care.
Limits
The abstract provides no quantitative data, search parameters, or study count. Evidence regarding recurrence risk specifically in patients treated with aromatase inhibitors remains inconclusive, and head-to-head comparative data between formulations are completely lacking.
Cited by
- supports The medical consensus is that women with a past history of breast cancer who cannot use systemic estrogen therapy may safely be candidates for vaginal estrogen use.